Biotech · Private company · Montrose, CA, US
Hillhurst Biopharmaceuticals, Inc.
Track this companyFree. Adds Hillhurst Biopharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- HBI-002Phase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- HBI-002Phase 1 · Anemia, Sickle CellClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's DiseasePHASE2 · RECRUITING · started Jun 30, 2026ClinicalTrials.gov NCT07005180 · fetched Nov 12, 2026
- A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy VolunteersPHASE1 · COMPLETED · started Jul 25, 2022ClinicalTrials.gov NCT03926819 · fetched Nov 12, 2026
NIH awards6
- HBI-002 to Treat Diabetic RetinopathyFiscal year 2025 · $961.2KNIH RePORTER 5R44EY033264-03 · fetched Nov 12, 2026
- HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell DiseaseFiscal year 2025 · $999.7KNIH RePORTER 5R44HL131065-07 · fetched Nov 12, 2026
- HBI-002 for Cystic FibrosisFiscal year 2024 · $300KNIH RePORTER 1R41HL167404-01A1 · fetched Nov 12, 2026
- HBI-002 to Treat Diabetic RetinopathyFiscal year 2024 · $950.2KNIH RePORTER 2R44EY033264-02A1 · fetched Nov 12, 2026
- Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell DiseaseFiscal year 2024 · $728.1KNIH RePORTER 4UH3NS127943-02 · fetched Nov 12, 2026
- HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell DiseaseFiscal year 2024 · $999.9KNIH RePORTER 5R44HL131065-06 · fetched Nov 12, 2026